About Hexamer Therapeutics
Hexamer Therapeutics is a private company based in Pullman, Washington. It has reported $1,620,990 raised in three offerings on Form D since December 2019. Its chief executive is Robert Bogden.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Sep 15, 2026 | $500,000of $2.5M target | 2 | $250K | Equity, OptionsRule 506(b) | Form D ↗ |
| Jan 1, 2024 | Jun 27, 2024 | $651,265of $6.6M target | 9 | $72,363 | Equity, OptionsRule 506(b) | Form D ↗ |
| Nov 15, 2019 | Dec 27, 2019 | $469,725of $1.1M target | 3 | $156K | Equity, OptionsRule 506(b) | Form D ↗ |
| Total, three offerings | $1,620,990 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Hexamer Therapeutics's Form D filed Sep 15, 2026.
BC
Brad Call
Director
RB
R. Scott Blackley
Director
CC
Colin Collins
Chief Scientific Officer and Co-Founder, director
SC
Stephen Crawford
Director